◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › REGN

Regeneron Pharmaceuticals Inc (REGN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-07-13

Regeneron Pharmaceuticals Inc (REGN) operates in the Biotechnology industry and is headquartered in Tarrytown, United States with about 15,343 employees. Its market capitalization is roughly $69 billion. In the fiscal year ended 2025-12-31, REGN reported $14.3B in revenue and $4.5B in net income.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Interactive charts & full statements → Open the REGN valuation workbench →

REGN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$14.9B	$14.3B	$14.2B	$13.1B	$12.2B	$16.1B	$8.5B	$7.9B	$6.7B	$5.9B	$4.9B	$4.1B	$2.8B	$2.1B	$1.4B	$446M	$459M	$379M	$238M	$125M	$63M
Gross Profit	$12.6B	$12.2B	$12.2B	$12.2B	$10.5B	$13.3B	$7.1B	$7.1B	$6.3B	$5.5B	$4.6B	$3.7B	$2.6B	$1.9B	$1.3B	$442M	$457M	$363M	$238M	$125M	$41M
Gross Margin %	84.5%	85.4%	86.1%	93.3%	86.0%	83.0%	84.0%	90.0%	93.5%	93.2%	93.8%	90.4%	92.7%	92.6%	93.9%	99.1%	99.5%	95.8%	99.6%	100.0%	64.2%
Operating Income (EBIT)	$3.6B	$3.6B	$4.0B	$4.0B	$5.4B	$8.9B	$3.6B	$2.2B	$2.5B	$2.1B	$1.3B	$1.3B	$838M	$760M	$458M	($205M)	($97M)	($74M)	($90M)	($114M)	($107M)
Operating Margin %	24.3%	24.9%	28.1%	30.9%	44.2%	55.7%	42.1%	28.1%	37.8%	35.4%	27.4%	30.5%	29.7%	36.1%	33.2%	-46.0%	-21.2%	-19.5%	-37.7%	-91.5%	-169.1%
Net Income	$4.4B	$4.5B	$4.4B	$4.0B	$4.3B	$8.1B	$3.5B	$2.1B	$2.4B	$1.2B	$896M	$636M	$348M	$424M	$750M	($222M)	($104M)	($68M)	($83M)	($106M)	($102M)
Net Margin %	29.6%	31.4%	31.1%	30.1%	35.6%	50.2%	41.3%	26.9%	36.4%	20.4%	18.4%	15.5%	12.3%	20.2%	54.4%	-49.7%	-22.8%	-17.9%	-34.7%	-84.5%	-161.3%
EBITDA	$5.7B	$5.8B	$5.3B	$4.0B	$5.3B	$9.7B	$4.1B	$2.4B	$2.7B	$2.2B	$1.4B	$1.3B	$891M	$801M	$495M	($174M)	($78M)	($55M)	($79M)	($82M)	($77M)
Earnings Per Share (EPS)	$41.04	$41.48	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.29	$10.34	$7.70	$5.52	$3.07	$3.81	$6.50	$-2.45	$-1.26	$-0.85	$-1.05	$-1.59	$-1.77
Shares Outstanding (M)	108M	109M	115M	114M	114M	112M	115M	115M	115M	116M	116M	115M	113M	111M	115M	91M	83M	80M	79M	66M	58M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$3.6B	$3.9B	$3.8B	$3.7B	$3.0B	$3.8B	$3.7B	$3.5B
Gross Profit	$2.9B	$3.3B	$3.2B	$3.1B	$2.6B	$3.2B	$3.2B	$3.1B
Gross Margin %	81.4%	85.0%	86.1%	85.6%	84.7%	85.1%	86.8%	86.5%
Operating Income (EBIT)	$643M	$880M	$1.0B	$1.1B	$592M	$990M	$1.2B	$1.1B
Operating Margin %	17.8%	22.7%	27.4%	29.4%	19.5%	26.1%	31.7%	30.1%
Net Income	$727M	$845M	$1.5B	$1.4B	$809M	$918M	$1.3B	$1.4B
Net Margin %	20.2%	21.7%	38.9%	37.9%	26.7%	24.2%	36.0%	40.4%
EBITDA	$967M	$1.2B	$1.9B	$1.7B	$1.0B	$1.1B	$1.6B	$1.8B
Earnings Per Share (EPS)	$6.75	$7.86	$13.62	$12.81	$7.27	$8.06	$11.54	$12.41
Shares Outstanding (M)	108M	108M	107M	109M	111M	114M	116M	115M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$5.0B	$5.0B	$4.4B	$4.6B	$5.0B	$7.1B	$2.6B	$2.4B	$2.2B	$1.3B	$1.5B	$1.3B	$752M	$589M	($75M)	($142M)	$96M	($72M)	($89M)	$27M	$23M
Capital Expenditures (CapEx)	$858M	$898M	$756M	$926M	$590M	$552M	$615M	$430M	$383M	$273M	$512M	$678M	$333M	$156M	$49M	$57M	$100M	$97M	$35M	$18M	$3M
Free Cash Flow (FCF)	$4.2B	$4.1B	$3.7B	$3.7B	$4.4B	$6.5B	$2.0B	$2.0B	$1.8B	$1.0B	$974M	$653M	$419M	$432M	($124M)	($199M)	($3M)	($170M)	($124M)	$9M	$20M
FCF Margin %	27.9%	28.4%	25.8%	28.0%	36.4%	40.6%	23.6%	25.4%	27.0%	17.6%	20.0%	15.9%	14.9%	20.5%	-9.0%	-44.6%	-0.7%	-44.7%	-52.0%	7.1%	31.9%
Dividends Paid	$374M	$370M	$0M	$0M	—	—	—	—	—	$359M	$500M	$547M	$295M	$0M	$0M	$0M	$0M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$1.1B	$1.2B	$1.6B	$1.1B	$1.0B	$1.3B	$1.3B	$354M
Capital Expenditures (CapEx)	$231M	$249M	$201M	$177M	$272M	$267M	$184M	$211M
Free Cash Flow (FCF)	$848M	$922M	$1.4B	$968M	$774M	$996M	$1.1B	$143M
FCF Margin %	23.5%	23.7%	37.8%	26.3%	25.5%	26.3%	29.8%	4.0%
Dividends Paid	$98M	$93M	$91M	$93M	$94M	—	—	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

REGN Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$40.9B	$40.6B	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B	$14.8B	$11.7B	$8.8B	$7.0B	$5.6B	$3.9B	$3.0B	$2.1B	$1.3B	$1.1B	$741M	$670M	$936M	$585M
Cash & Cash Equivalents	$3.0B	$3.1B	$2.5B	$2.7B	$3.1B	$2.9B	$2.2B	$1.6B	$1.5B	$813M	$535M	$809M	$649M	$536M	$230M	$484M	$113M	$207M	$248M	$499M	$238M
Total Liabilities	$9.4B	$9.3B	$8.4B	$7.1B	$6.5B	$6.7B	$6.1B	$3.7B	$3.0B	$2.6B	$2.5B	$2.0B	$1.3B	$999M	$835M	$838M	$562M	$344M	$251M	$476M	$368M
Total Debt (Short + Long-Term)	$2.7B	$2.0B	$2.0B	$2.0B	$2.7B	$2.7B	$3.6B	$0M	$91M	$1.2B	$481M	$816M	$497M	$321M	$298M	$276M	$160M	$109M	$162M	$200M	$221M
Total Shareholders' Equity	$31.4B	$31.3B	$29.4B	$26.0B	$22.7B	$18.8B	$11.0B	$11.1B	$8.8B	$6.1B	$4.4B	$3.7B	$2.5B	$2.0B	$1.2B	$486M	$528M	$397M	$419M	$460M	$217M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive REGN viewer.

Other Companies in Biotechnology

ABBV · AbbVie — $458 billion
AMGN · Amgen — $203 billion
GILD · Gilead Sciences — $161 billion
VRTX · Vertex Pharmaceuticals — $121 billion
BIIB · Biogen — $30 billion
ROIV · Roivant Sciences Ltd. — $26 billion
INSM · Insmed Incorporated — $26 billion
INCY · Incyte — $24 billion

← REG All stocks REKR →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.